"Grab a rising star, rather than a falling knife JOHN BEVERIDGE HERALD SUN OCTOBER 30, 2013 10:00PM
"Another fast rising stock worth a second look is drug developer Invion.
Run by former Chemgenex boss Dr Greg Collier and with a US clinical team led by prolific drug developer Dr Mitchell Glass, Invion has acquired rights to expand its range of potential treatments to asthma, chronic obstructive pulmonary disease, cystic fibrosis, lupus and smoking cessation.
The toughest part in developing drugs is getting them past the US Food and Drug Administration so the combination of using some existing drugs repurposed for inhalation and an experienced team should fast track the clinical pathway.
Invion shares have leapt since my first speculative buy in February but the call remains in place as phase two trials reduce risk and bring Invion closer to a deal with a major pharmaceutical partner."
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)